Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Jasper Therapeutics Inc (JSPRW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: JSPRW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit 26.17% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.73 | 52 Weeks Range 0.06 - 0.25 | Updated Date 05/31/2025 |
52 Weeks Range 0.06 - 0.25 | Updated Date 05/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.84 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -56.5% | Return on Equity (TTM) -101.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 9908441 |
Shares Outstanding - | Shares Floating 9908441 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Jasper Therapeutics Inc
Company Overview
History and Background
Jasper Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of conditioning agents for hematopoietic stem cell transplantation (HSCT) and engineered cell therapies. Founded with the goal of improving outcomes for patients undergoing these procedures, the company aims to reduce toxicity and expand the applicability of HSCT.
Core Business Areas
- Hematopoietic Stem Cell Transplantation (HSCT) Conditioning: Jasper Therapeutics develops and seeks to commercialize conditioning agents designed to prepare patients for HSCT. This involves reducing existing blood cells to create space for transplanted cells.
- Engineered Cell Therapy Conditioning: The company is also focused on developing conditioning agents to improve the efficacy and safety of engineered cell therapies, such as CAR-T cell therapy.
Leadership and Structure
Ronald Martell serves as the President and CEO. The company has a management team with experience in drug development, regulatory affairs, and commercialization. The organizational structure includes departments for research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- Buldoximab: Buldoximab is the company's lead product candidate, an anti-CD117 antibody designed to clear hematopoietic stem cells. It is currently in clinical development for use as a conditioning agent prior to hematopoietic stem cell transplantation. Market share is currently 0 as product is not yet commercialized. Competitors in conditioning regimens include traditional chemotherapy and radiation. Companies developing alternative conditioning agents include Gamida Cell (GMDA), although the approaches are different.
Market Dynamics
Industry Overview
The HSCT market is characterized by significant unmet needs, particularly regarding toxicity and applicability to a broader patient population. The engineered cell therapy market is rapidly growing, driven by advances in CAR-T cell therapy and other cell-based treatments.
Positioning
Jasper Therapeutics aims to differentiate itself by developing safer and more targeted conditioning agents that can expand the use of HSCT and engineered cell therapies. Their focus is on addressing the limitations of current conditioning regimens.
Total Addressable Market (TAM)
The global hematopoietic stem cell transplantation market is estimated to be in the billions of USD annually. The cell therapy market is also in the billions and is growing rapidly. Jasper Therapeutics is positioned to capture a portion of this market by providing improved conditioning agents.
Upturn SWOT Analysis
Strengths
- Novel technology platform focused on targeted conditioning.
- Potential to reduce toxicity associated with traditional conditioning regimens.
- Experienced management team.
- Addresses a significant unmet medical need.
Weaknesses
- Single lead product candidate creates risk.
- Clinical development is inherently uncertain.
- Reliance on successful clinical trials and regulatory approval.
- Limited financial resources as a development-stage company.
Opportunities
- Expansion of buldoximab to other indications.
- Partnerships with companies developing engineered cell therapies.
- Potential for breakthrough therapy designation and accelerated approval.
- Growing market for HSCT and cell therapies.
Threats
- Competition from established conditioning regimens.
- Regulatory hurdles and potential for clinical trial failure.
- Development of alternative conditioning approaches by competitors.
- Economic downturn impacting healthcare spending.
Competitors and Market Share
Key Competitors
- GMDA
- TAK
- BIIB
- BMY
- GILD
Competitive Landscape
Jasper Therapeutics is attempting to enter a market dominated by established companies that primarily focus on chemotherapy and radiation-based conditioning. Jasperu2019s advantage lies in a more targeted approach that aims to reduce toxicity and expand the use of stem cell transplants. Current competitors have significant advantages in terms of market share and financial resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of buldoximab through clinical trials.
Future Projections: Future growth depends on the successful completion of clinical trials, regulatory approval, and commercialization of buldoximab. Analyst estimates vary depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include the ongoing clinical trials of buldoximab and efforts to secure partnerships.
Summary
Jasper Therapeutics is a development-stage biotech company focused on HSCT conditioning with a novel approach to reduce toxicity. The company's success hinges on the clinical trial outcomes of buldoximab. While the targeted approach offers a competitive advantage, the company faces risks related to clinical development and competition from established players. The company's financial health and the pace of buldoximab's development will be critical to its long-term prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Jasper Therapeutics Inc. SEC Filings
- Company Press Releases
- Analyst Reports
- Industry Research Reports
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jasper Therapeutics Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2020-01-10 | President, CEO & Director Mr. Ronald A. Martell | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://jaspertx.com |
Full time employees 64 | Website https://jaspertx.com | ||
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.